AbCellera Biologics Inc. Stock

Equities

ABCL

CA00288U1066

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
3.9 USD -1.76% Intraday chart for AbCellera Biologics Inc. -0.51% -31.70%
Sales 2024 * 47.81M Sales 2025 * 64.33M Capitalization 1.14B
Net income 2024 * -190M Net income 2025 * -219M EV / Sales 2024 * 20 x
Net cash position 2024 * 183M Net cash position 2025 * 79.31M EV / Sales 2025 * 16.5 x
P/E ratio 2024 *
-6.44 x
P/E ratio 2025 *
-6.26 x
Employees 586
Yield 2024 *
-
Yield 2025 *
-
Free-Float 71.9%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AbCellera Biologics Inc.

1 day-1.76%
1 week-0.51%
Current month-13.91%
1 month-15.03%
3 months-25.86%
6 months-12.36%
Current year-31.70%
More quotes
1 week
3.79
Extreme 3.79
4.31
1 month
3.79
Extreme 3.79
4.75
Current year
3.79
Extreme 3.79
6.06
1 year
3.79
Extreme 3.79
8.05
3 years
3.79
Extreme 3.79
36.05
5 years
3.79
Extreme 3.79
71.91
10 years
3.79
Extreme 3.79
71.91
More quotes
Managers TitleAgeSince
Founder 39 12-11-07
Founder - 12-11-07
Chief Executive Officer 49 12-11-07
Members of the board TitleAgeSince
Director/Board Member 59 20-10-31
Director/Board Member 72 19-09-30
Director/Board Member 63 21-12-06
More insiders
Date Price Change Volume
24-04-24 3.9 -1.76% 1,599,034
24-04-23 3.97 -1.00% 1,595,129
24-04-22 4.01 +3.62% 1,076,281
24-04-19 3.87 -1.02% 978,622
24-04-18 3.91 -0.26% 765,647

Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT

More quotes
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.9 USD
Average target price
14.75 USD
Spread / Average Target
+278.21%
Consensus